DXB (DXB) News
Follow DXB (DXB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
DXB: Late-stage kidney disease pipeline with global deals and strong IP drives diversified growth
Two late-stage assets target high unmet needs in kidney disease: DMX-200 for FSGS is in Phase 3 with global licensing deals valued up to AU$1.9 billion, while DMX-652 for AKI is Phase 2 ready with a unique mitophagy mech
EQUITY | Sep 06, 2026, 11:37 PM UTC
L
Dimerix Facility Gives Fincl Flexibility Without Diluting Shareholders >DXB.AU
Dimerix Facility Gives Fincl Flexibility Without Diluting Shareholders >DXB.AU
EQUITY | Sep 04, 2026, 11:03 AM UTC
L
Dimerix to draw down only 50% of initial commitment for DXB
Dimerix will draw down only 50% of the amount committed initially for DXB.AU.
EQUITY | Sep 04, 2026, 11:02 AM UTC
L
DXB option to secure up to A$50M before 31 March
DXB has an option to secure up to A$50M before 31 March.
EQUITY | Sep 04, 2026, 11:01 AM UTC
M
Dimerix agrees A$34M non-dilutive loan via DXB.AU
Dimerix has agreed to an A$34M non-dilutive loan tied to DXB.AU.
EQUITY | Sep 04, 2026, 11:01 AM UTC
M
Dimerix secures A$34 million non-dilutive loan facility
Dimerix has secured non-dilutive loan facility agreements to fund key clinical milestones, totaling A$34 million.
EQUITY | Sep 04, 2026, 03:00 AM UTC
M
Dimerix secures A$34 million non-dilutive funding facility
Dimerix Ltd (ASX:DXB) secured an A$34 million non-dilutive funding facility.
EQUITY | Sep 04, 2026, 01:12 AM UTC
L
DXB price target raised 6.5% to A$2.45 by Euroz Hartleys
Euroz Hartleys raised its DXB price target 6.5% to A$2.45 per share.
EQUITY | Sep 04, 2026, 12:44 AM UTC
L
Dimerix requests trading halt pending announcement on non-dilutive funding
Dimerix Ltd (ASX: DXB) has requested a trading halt pending an announcement on non-dilutive funding arrangements.
EQUITY | Sep 01, 2026, 10:45 PM UTC
M
Dimerix posts A$29.8 million loss for the year
Dimerix Ltd reported a year loss attributable to A$29.8 million.
EQUITY | Aug 27, 2026, 01:37 AM UTC
M
DXB net loss rises to $29.8M amid R&D, licensing and pipeline expansion
DXB reported a net loss of $29.8M, citing higher R&D alongside major licensing and pipeline expansion.
EQUITY | Aug 26, 2026, 11:19 PM UTC